Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
600196
株式のランク
#2198
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical... Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
株価
$3.40
時価総額
$9.07B
変化（1日）
-1.61%
変化（1年）
-16.08%
国
CN
取引 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
カテゴリー
Healthcare
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.（600196）の収益
Oct 2026 時点の収益 TTM: 0
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. の収益履歴（2001 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2025 | $5.93B | 5.44% |
| 2024 | $5.63B | -3.80% |
| 2023 | $5.85B | -8.21% |
| 2022 | $6.37B | 3.81% |
| 2021 | $6.14B | 32.30% |
| 2020 | $4.64B | 13.01% |
| 2019 | $4.11B | 13.32% |
| 2018 | $3.62B | 27.17% |
| 2017 | $2.85B | 35.20% |
| 2016 | $2.11B | 8.52% |
| 2015 | $1.94B | 0.01% |
| 2014 | $1.94B | 17.81% |
| 2013 | $1.65B | 39.99% |
| 2012 | $1.18B | 14.43% |
| 2011 | $1.03B | 49.06% |
| 2010 | $690.17M | 22.38% |
| 2009 | $563.96M | 1.99% |
| 2008 | $552.97M | 9.32% |
| 2007 | $505.81M | -3.27% |
| 2006 | $522.92M | 41.24% |
| 2005 | $370.24M | 27.18% |
| 2004 | $291.11M | 11.82% |
| 2003 | $260.35M | 108.87% |
| 2002 | $124.64M | 41.71% |
| 2001 | $87.96M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
